Prelude Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Prelude Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,627	Closed	-$80K	–	1381
2022 Q3	$80K	Sell	4,627 -1,683	-27%	-$28.9K	﹤0.01%	1194
2022 Q2	$69K	Buy	6,310 +1,297	+26%	+$18.6K	﹤0.01%	1461
2022 Q1	$111K	Buy	5,013 +1,134	+29%	+$27.3K	﹤0.01%	1390
2021 Q4	$133K	Buy	3,879 +1,752	+82%	+$82.8K	﹤0.01%	1660
2021 Q3	$131K	Sell	2,127 -378	-15%	-$24.7K	﹤0.01%	1458
2021 Q2	$195K	Buy	+2,505	New	+$157K	0.01%	1386
2019 Q4	–	Sell	-50	Closed	-$12K	–	1971
2019 Q3	$12K	Buy	+50	New	+$10.8K	﹤0.01%	1469

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TFS

TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's CYCN Position: Q4 2022 in Review

Prelude Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2022, closing a stake of 4,627 shares — an estimated $80K sold.

Prelude Capital Management first reported a position in CYCN in Q3 2019 and held it in 7 quarters. The position peaked at $195K in Q2 2021. 40 funds tracked by Wall St. Rank hold CYCN as of Q4 2022.

Prelude Capital Management reported no remaining Cyclerion Therapeutics position as of Q4 2022 after selling out during the quarter.
Prelude Capital Management sold 4,627 Cyclerion Therapeutics shares in Q4 2022, an estimated $80K.
Prelude Capital Management first reported a position in Cyclerion Therapeutics in Q3 2019 and held it in 7 quarters.
Prelude Capital Management's Cyclerion Therapeutics position peaked at $195K in Q2 2021.
40 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.